Skip to main content

Table 1 Relative susceptibility (RS) and relative efficacy (RE)

From: Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors

Condition RS(24) RE(24) RS(48) RE(48)
(K-Ras, REGO) 2.31 0.23 1.64 0.31
(K-Ras, PI3K-i) 0.59 0.53 0.52 1.10
(K-Ras, MEK-i) 1.22 0.51 1.27 0.48
(K-Ras/PI3K, REGO) 0.77 1.28 1.05 1.06
(K-Ras/PI3K, PI3K-i) 1.38 0.35 0.88 0.93
(K-Ras/PI3K, MEK-i) 0.99 0.70 1.25 0.77
  1. Two measures are calculated in the original space for two different times following treatment